{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:57:35Z","timestamp":1765742255058,"version":"3.48.0"},"reference-count":30,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,11,7]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Aortic stenosis (AS) is one of the most common acquired cardiac valvular diseases. The success of transcatheter aortic valve implantation (TAVI) for severe AS has led to increasing interest in its use to earlier disease\u2014moderate AS (MAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Model-based study using a Markov microsimulation technique to evaluate the long-term costs and benefits associated with \u2018early\u2019 TAVI. Key data inputs were sourced from the international literature and costs were obtained from Australian sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Australian health care system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>10 000 hypothetical MAS patients with or without left ventricular diastolic dysfunction or impaired left ventricular ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Comparing early TAVI to medical management over a life time horizon for MAS patients aged &gt;65 years. We evaluated the cost-effectiveness of offering early TAVI in five scenarios (10%, 25%, 50%, 75% and 90% take-up rates).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome measure is quality-adjusted life years (QALY) gained and the incremental cost\u2013utility ratio (ICUR). Secondary outcomes are life-years gained and the number of heart failure case avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Offering early TAVI for MAS patients resulted in both higher healthcare costs and greater benefits (an increase of 3.02 QALYs or 3.99 life-years) per person treated. The ICUR was around $A10\u2009867 and $A11\u2009926 per QALY gained for all five scenarios, with the total cost of early TAVI to the healthcare system being anticipated to be up to $A3.66\u2009billion. Sensitivity analyses indicated a 100% probability of being cost-effective with a willingness to pay threshold of $A50 000\/QALY. The benefits remained, even with assumptions of high levels of repeat valve replacement after TAVI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While ongoing randomised controlled trials will define the benefit of TAVI to MAS patients, these results suggest that this intervention is likely to be cost-effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-073254","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T12:35:42Z","timestamp":1700656542000},"page":"e073254","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits \u2013 a Markov model-based simulation study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-4510","authenticated-orcid":false,"given":"Dieu","family":"Nguyen","sequence":"first","affiliation":[{"name":"Deakin Health Economics, Institute for Health Transformation, School of Health and Social Development, Deakin University Faculty of Health, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Marwick","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marj","family":"Moodie","sequence":"additional","affiliation":[{"name":"Deakin Health Economics, Institute for Health Transformation, School of Health and Social Development, Deakin University Faculty of Health, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-1140","authenticated-orcid":false,"given":"Lan","family":"Gao","sequence":"additional","affiliation":[{"name":"Deakin Health Economics, Institute for Health Transformation, School of Health and Social Development, Deakin University Faculty of Health, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"2025121411540902000_13.11.e073254.1","first-page":"e25","article-title":"ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2025121411540902000_13.11.e073254.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008232"},{"key":"2025121411540902000_13.11.e073254.3","doi-asserted-by":"crossref","unstructured":"Kolkailah AA , Doukky R , Pelletier MP , et al . Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. Cochrane Database Syst Rev 2019;12. doi:10.1002\/14651858.CD013319.pub2","DOI":"10.1002\/14651858.CD013319.pub2"},{"key":"2025121411540902000_13.11.e073254.4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2020.12.052","article-title":"Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk","volume":"77","author":"Leon","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025121411540902000_13.11.e073254.5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.carrev.2020.01.009","article-title":"Cost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in Low- to intermediate-surgical-risk patients","volume":"21","author":"Azraai","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"key":"2025121411540902000_13.11.e073254.6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2018.3152","article-title":"Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics","volume":"3","author":"Lancellotti","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025121411540902000_13.11.e073254.7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4070\/kcj.2020.0037","article-title":"Early surgery versus watchful waiting in patients with moderate aortic stenosis and left ventricular systolic dysfunction","volume":"50","author":"Moon","year":"2020","journal-title":"Korean Circ J"},{"key":"2025121411540902000_13.11.e073254.8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tcm.2020.10.002","article-title":"Asymptomatic severe aortic stenosis, bicuspid aortic valves and moderate aortic stenosis in heart failure: new indications for Transcatheter aortic valve implantation","volume":"31","author":"S\u00e1","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"2025121411540902000_13.11.e073254.9","unstructured":"Pharmaceutical Benefits Advisory Committee . Guidelines for preparing submissions to the pharmaceutical benefits advisory committee. 2016. Available: https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf"},{"key":"2025121411540902000_13.11.e073254.10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.jacc.2021.09.861","article-title":"Life expectancy after surgical aortic valve replacement","volume":"78","author":"Martinsson","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025121411540902000_13.11.e073254.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.961839"},{"key":"2025121411540902000_13.11.e073254.12","unstructured":"Australian Institute of Health and Welfare . Health expenditure Australia 2017\u201318. 2019 Available: https:\/\/www.aihw.gov.au\/reports\/health-welfare-expenditure\/health-expenditure-australia-2017-18"},{"key":"2025121411540902000_13.11.e073254.13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.hlc.2020.09.934","article-title":"Cost-effectiveness of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis","volume":"30","author":"Zhou","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2025121411540902000_13.11.e073254.14","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000414","article-title":"Severe symptomatic aortic stenosis: medical therapy and transcatheter aortic valve implantation (tavi)\u2014a real-world retrospective cohort analysis of outcomes and cost-effectiveness using national data","volume":"3","author":"Freeman","year":"2016","journal-title":"Open Heart"},{"key":"2025121411540902000_13.11.e073254.15","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"2025121411540902000_13.11.e073254.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031033","article-title":"Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure","volume":"9","author":"Gao","year":"2019","journal-title":"BMJ Open"},{"key":"2025121411540902000_13.11.e073254.17","unstructured":"Shardey G , Tran L , Williams-Spence JS , et al . The Australian and New Zealand society of cardiac and Thoracic Surgeons cardiac surgery database. 2020. Available: https:\/\/7n4ik1cb2c61rz1rl1tw7m9t-wpengine.netdna-ssl.com\/wp-content\/uploads\/2020\/11\/ANZSCTS-Database-2019-National-Annual-Report.pdf"},{"key":"2025121411540902000_13.11.e073254.18","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/S0140-6736(15)60290-2","article-title":"5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial","volume":"385","author":"Kapadia","year":"2015","journal-title":"The Lancet"},{"key":"2025121411540902000_13.11.e073254.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.004"},{"key":"2025121411540902000_13.11.e073254.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.04.054"},{"key":"2025121411540902000_13.11.e073254.21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.hlc.2021.07.017","article-title":"2021 CSANZ and ANZSCTS position statement on the operator and institutional requirements for a transcatheter aortic valve implantation (TAVI) program in Australia","volume":"30","author":"Bennetts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2025121411540902000_13.11.e073254.22","unstructured":"Medicare Benefits Schedule . MBS online - MBS listing for Transcatheter aortic valve implantation (TAVI). 2017. Available: MBS online - MBS Listing for Transcatheter Aortic Valve Implantation (TAVI)"},{"key":"2025121411540902000_13.11.e073254.23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/fca.14.33","article-title":"Challenges in the echocardiographic assessment of aortic stenosis","volume":"10","author":"Khan","year":"2014","journal-title":"Future Cardiol"},{"key":"2025121411540902000_13.11.e073254.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.10.032"},{"key":"2025121411540902000_13.11.e073254.25","first-page":"938","article-title":"Incidence and outcomes of acute coronary syndrome after transcatheter aortic valve replacement","volume":"13","author":"Mentias","year":"2020","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2025121411540902000_13.11.e073254.26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamacardio.2017.3425","article-title":"Association of paravalvular regurgitation with 1-year outcomes after transcatheter aortic valve replacement with the SAPIEN 3 valve","volume":"2","author":"Pibarot","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025121411540902000_13.11.e073254.27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4244\/EIJ-D-17-00603","article-title":"Beyond the five-year horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices","volume":"14","author":"Deutsch","year":"2018","journal-title":"EuroIntervention"},{"key":"2025121411540902000_13.11.e073254.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.051"},{"key":"2025121411540902000_13.11.e073254.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.037"},{"key":"2025121411540902000_13.11.e073254.30","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.10.020801","article-title":"Association between social participation and cognitive function among middle-and old-aged Chinese: a fixed-effects analysis","volume":"10","author":"Zhou","year":"2020","journal-title":"J Glob Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-073254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:54:19Z","timestamp":1765742059000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-073254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,22]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bmjopen-2023-073254"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-073254","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}